Oxeltis is delighted to welcome Christophe Parsy as Director of Sales and Strategy Development.
Christophe Parsy brings more than 25 years of experience in the pharmaceutical sector (CRO, biotech, and large groups) to the company. He has extensive expertise in anti-infectives (HIV, HCV, etc.), antimicrobials, oncology, and small molecule chemistry, having contributed to the development of several clinical candidates.
His expertise spans small molecules, prodrugs, DNA-encoded libraries, AI-assisted design, Fragment-Based Drug Design (FBDD), and targeted protein degradation. As Head of Medicinal Chemistry, then Senior Leader of Integrated Drug Discovery at Oncodesign Services, he led preclinical projects, oversaw strategic alliances, conducted due diligence, and promoted the company’s integrated discovery capabilities internationally.
As Director of Business and Strategic Development at Oxeltis, Christophe blends scientific and strategic vision to build strong partnerships, identify new opportunities, and position the company as a key player in early-stage drug discovery innovation, particularly in the areas of small molecules, targeted protein degradation, and complex nucleoside/nucleotide chemistry.
By aligning Oxeltis’ expertise with customer and market needs, he plays a central role in accelerating innovation-driven growth, expanding the company’s global visibility, and strengthening its position as a trusted partner in medicinal chemistry research services.
